Member Info for Laura2022

Usually a buy like that would be reported 1hr or even 1day late

The fact it was live and so much above the ask suggests someone wanted in quickly

£13.2m loan secured to fund future capital investment

 

Customer highlights

· Increased order book by £100m (lifetime value) to £390m at the end of the year

· Further demonstrated the ability to win "carry over" business with existing customer OEM 10

· 5 contracts in multi-year revenue generation phase

· Customers have been critical but supportive in response to our production difficulties

Apparently this was posted last night in telegram

Rumoured possible Cheap OEM or strategic take over here.. what price will it be?.. probs around 1p imo, thats after having taken a big stake last week. Around 40% stock sold… decent 15m block buy late Friday too at 0.53p someone wanting the stock!.… expecting fire works here soon. If the OEM’s have £400m of orders awaiting delivery then makes total sense to take the lot ..cheap.. they’ll save a packet on costs and can then ride out the development phases taking all the spoils when completed. Not rocket science here, especially with £100m spent to date.

But unfortunately at the moment the majority of people with cancer see no benefit from immunotherapy.

Many suffer a relapse or experience significant side effects, which can include painful inflammation in the bowel, skin or the lungs.

So now a new multimillion-pound research programme aims to discover why at least half of all patients fail to respond to immunotherapy or suffer from those debilitating side effects

Thanks Ralph

With the beyondblood/PYC test developing well and the OBD cancer prostate test clearly not selling (see their last 2yrs financial results) , is there now a huge gap for the test developed by PYC/BB

Clearly someone wanted to buy in size and quirky

A) directors

B) funds buying off another

C) someone with wind of poster news

Any other thoughts?

Thanks for the link Trench

As you say, a good chance PYC could be involved

A virtuous circle'

Funding for the project comes from various sources, including £9m from the government-run Office for Life Sciences and the Medical Research Council - two organisations that support research and innovation to improve healthcare in the UK. An additional £12.9m comes from industry.

The project is part of a bigger commitment from the Department of Science, Innovation and Technology for £145m to support cancer diagnosis and treatment and has the backing of Science and Technology Minister Peter Kyle.

"Cancer is a disease that has brought pain, misery and heartbreak to every family in the country, including my own," he said.

"But through government working in partnership with the NHS, researchers, and business, we can harness science and innovation to bring the detection and treatment of this horrendous disease firmly in to the 21st Century, keeping more families together for longer.

"The UK’s scientists, researchers and captains of industry have brilliant ideas that aren’t just going to boost our health - they’ll boost our economy too, helping to build a virtuous circle for more investment in both health and research which will ultimately drive up living standards."

5hrs to reply

You need medical help or anger mgmt

Having seen your last 12mths of discussion I've filtered you SL10

Gluck

I'm happy to be buying at all time lows

Thanks for your concern

Yes threeputt

I have no idea what motovats these people when they're MO is apparent from the things they give away ..eg he's known /invested for many years BUT only joined LSE July 2024 and 99% is vitriol and nastiness and not one single share investment as you say

His family must be proud

Cost and time savings

Through the prediction of research outcomes, the most promising approaches can be prioritised, enabling fewer more targeting experiments, and smaller, more efficient trial designs. MIDD helps avoid redundant research by using existing data and models to inform new research.

Regulatory support

Regulators are increasingly seeing the value of MIDD in providing supporting evidence for efficacy, providing rationale to trail design – including optimised drug dosing, and prediction of drug safety. Agencies such as the FDA and EMA now actively support and encourage the use of such techniques in submissions.

We have experience in the design and delivery of clinical trials from Phase 1 (e.g. bioequivalence, dose-escalation and dose proportionality) to phase II, through to phase III.

Our solutions include, but are not limited to:

Trial Setup

Clinical Trial Design (early to late phase)

Effective endpoint identification

Sample size and power calculations using standard and simulation approaches

Protocol and Statistical Analysis Plan (SAP) development

Data Capture Design (CRF)

Regulatory Trial Submission Support

Trial Conduct and Reporting

Interim Analysis

Adaptive trial design gating decisions

Final Analysis and Reporting (TFLs Post-hoc analysis)

Performing analysis validation

Statistical Analysis Report interpretation

Clinical Study Report (CSR) Development

Advice and Support

Biostatistics oversight of CRO/Vendor

Biostatistical Advice

Regulatory Meeting Support

Innovative Modelling and Simulation

Meta analysis and Bayesian analysis

Data Driven decision making

Which shares DO you recommend

Apart from GDR which you went quiet on

You clearly have re incarnated to troll AGL APTA ( though you also go hot and cold there too) and SCE

Which shares do you ACTUALLY hold

"Wider business update "

provide a live presentation relating to the Company's full year results and wider business update via Investor Meet Company on 7 October 2024 at noon BST.

It was a live trade hence the date stamp

Looks like the cst has got your tongue

Really??

Who is going to buy out GDR...since this comment you've gone silent

GordonGecko123

Posted in: GDR

Posts: 180

Price: 2.10

No Opinion

RE: NHS14 Sep 2024 15:18

I would expect more than 3p given the huge market opportunity with the NHS it presents . Then there iarenother markets around the world . That's why I think this will get bought out especially when FDA approval is received

I'd say you're full of s#hite